Real-world clinical outcomes of cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: a retrospective US claims analysis.
Saved in:
| Title: | Real-world clinical outcomes of cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: a retrospective US claims analysis. |
|---|---|
| Authors: | Ahn DH; Department of Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, United States., Park NJ; Department of Medical Affairs, Exelixis, Inc., Alameda, CA 94502, United States., Locker M; Department of Medical Affairs, Exelixis, Inc., Alameda, CA 94502, United States., Zhou ZY; Analysis Group, Inc., Boston, MA 02199, United States., Nie X; Analysis Group, Inc., Boston, MA 02199, United States., Wang T; Analysis Group, Inc., Boston, MA 02199, United States., Yu S; Department of Medical Affairs, Exelixis, Inc., Alameda, CA 94502, United States. |
| Source: | The oncologist [Oncologist] 2025 Sep 01; Vol. 30 (9). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
